Patent · US Active

Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer

US9296736B2 · kind B2 · utility

7Cited by

12References

13Claims

0Family size

Assignee

AMGEN INC. · US

Inventors

Michael D. Bartberger · West Hollywood, US
Ana Z. Gonzalez Buenrostro · San Mateo, US
Hilary Plake Beck · Emerald Hills, US
Xiaoqi Chen · Palo Alto, US
Richard V. Connors · Mesa, US
Jeffrey Deignan · San Francisco, US
Jason A. Duquette · Millbrae, US
John Eksterowicz · Burlingame, US
Benjamin Fisher · San Mateo, US
Brian M. Fox · Brisbane, US
Jiasheng Fu · Foster City, US
Zice Fu · Foster City, US
Felix Gonzalez Lopez De Turiso · San Mateo, US
Michael W. Gribble, Jr. · San Francisco, US
Darin J. Gustin · Rue de l'Église, US
Julie Anne Heath · Chico, US
Xin Huang · Brookline, US
XianYun Jiao · Belmont, US
Michael G. Johnson · San Diego, US
Frank Kayser · San Francisco, US
David John Kopecky · West Hollywood, US
SuJen Lai · Burlingame, US
Yihong Li · Millbrae, US
Zhihong Li · San Jose, US
Jiwen Liu · Winston-Salem, US
Jonathan D. Low · Thousand Oaks, US
Brian S. Lucas · Arlington, US
Zhihua Ma · Lexington, US
Lawrence R. McGee · Pacifica, US
Joel McIntosh · Pacifica, US

Key dates

Filing date	Jun 26, 2014
Grant date	Mar 29, 2016
Priority date	—
Expiry date	Jun 26, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/20
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention provides MDM2 inhibitor compounds of Formula I,

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.